Innovest Global, Inc. Stock Symbol IVST is a Public diversified Holding company that is already a ten-bagger (Up 1000% in the market) this year with much more on the way based on fundamentals AND technical from our research. Here’s what we found:
Innovest Global, Inc. (OTC Markets: IVST) is fundamentally in the Conglomerates industry. IVST is a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. The primary growth strategy of IVST is to acquire niche, high-growth businesses that are capable of generating significant annual revenue and that fit with other subsidiaries in their divisions. Planned subsidiaries operate across telehealth, biotech, building materials, commercial energy, business-to-business distribution, national call center and auto sales. Since January IVST has acquired 5 companies and those subsidiaries have grown in revenue 50% post acquisition. That means that when IVST buys a company, that company grows after the acquisition exponentially.
Based out of Cleveland, Ohio, IVST is easily one of the better fundamental companies trading on the OTC marketplace and in fact is Ohio’s fastest growing publicly traded company. Innovest Global, Inc. is already up 10-fold in 2018 after starting off in Jan around $0.02. Since then the stock hit a YTD all-time high of $0.55 in March 2018 it has since settled into a strong support around .23-.25. IVST continues to hold onto the substantial gains thus far and from our estimates is ready for the next leg, which we hope will be into the .50 range. Based upon the company’s strong fundamental AND technical picture, Innovest Global, Inc. could easily retake its all-time high by the end of 2018.
What a stock structure IVST has folks! The company has an amazing unchanged free-trading float of 11,796,710 common shares with no convertible debts, no warrants or options outstanding, and employs 45.
Onto the meat and potatoes:
IVST owns 20% of StemVax Therapeutics, which happens to be the first company in its Biotech Division.
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. Lead by world-renowned neuroscientist, Dr. Dwain Morris-Irvin, the Biotech & Health Sciences Division is currently focused on commercializing StemVax’s cancer vaccination therapy technology. The cancer vaccination therapy technology was just recently awarded a U.S. patent! We seek to make a difference in patient’s lives bringing new beginnings to the market by developing novel therapeutics.
IVST’s management team has been extremely busy with its pending mega-acquisition of a building materials company, which produces $30 million in annual revenues! Once the building materials company is acquired, it will serve as Innovest Global’s third division. The initial discussions began back in March 2018, followed by formal negotiations in April 2018. In June, Innovest management formally proposed the acquisition pitch to the target company’s board of directors. Upon conclusion of the presentation, both parties had signed and executed a Letter of Intent (LOI) document. In late August 2018, it was announced that both parties have effectively reached an agreement on the acquisition transaction structure and long form documents. We expect this to “formally” close at any moment.
IVST has the vision and model of Berkshire-Hathaway; we look forward to its evolution!